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Fragile x syndrome (FXS) is thought to be the most common inherited form of 
intellectual and developmental disability and the most common known single gene 
cause of autism. The prevalence of FXS is approximately 1.4 per 10,000 males and 0.9 
per 10,000 females. Learning difficulties in people with FXS can vary from mild to 
severe however it is most common to be within the mild to moderate range, with 
males often more affected than females. The current medical treatments for FXS are 
primarily symptomatic in nature; and include the use of selective serotonin reuptake 
inhibitors for anxiety, stimulants for attention deficit hyperactivity disorder and 
antipsychotics for irritability or aggressive behaviour.  However, our understanding 
of FXS has now progressed to a stage where treatments selected to target the 
underlying neurobiology are now being trialled. Experience conducting research 
studies at The Patrick Wild Centre into this condition has suggested that some families 
are reluctant to take part in clinical trials making recruitment challenging. Therefore, 
this study was designed to understand barriers to participation specifically amongst 
patients with the condition and their families. 
 
The primary aim of this study was to identify the barriers to research participation. 
The second aim of the study was to find out how barriers to clinical trial participation 
could be overcome in order to maximise recruitment for future studies. A mixed 
method design was used to collect both quantitative and qualitative data. Participants 
were identified from the UK Fragile X Society mailing list by a member of the Fragile 
X Society, The Patrick Wild Centre mailing list and through advertisements on the 
Patrick Wild Centre website, Facebook and Twitter feeds. A quantitative 
questionnaire was completed by 328 parents, carers, family members of individuals 
with FXS or by individuals with FXS. Following this, three focus groups took place in 




This study demonstrated that there are many different factors which may negatively 
influence motivation to participate in a clinical trial in this group.  However, the main 
barriers to participation were concerns about possible side effects, travel, requirement 
for blood tests and financial reasons. When these were explored further during focus 
groups it was evident that these barriers were not as clear as they may have appeared 
and had many complexities to them. The main way to overcome barriers that was 
repeatedly discussed in each focus group was the importance of accessible 
information in helping families to understand the study including any potential safety 
issues.  This study highlights that while there is no one thing that researchers can do 
that will work for everyone, there are many things that researchers can do to improve 






Fragile x syndrome (FXS) is thought to be the most common genetic cause of 
intellectual and developmental disability and an important cause of autism. It is 
thought that it occurs in 1.4 per 10,000 males and 0.9 per 10,000 females. Learning 
difficulties in people with FXS can vary from mild to severe however they are most 
commonly within the mild to moderate range, with males often more affected than 
females. The current medical treatments for FXS are primarily to treat symptoms 
related to the disorder, as opposed to being targeted at the underlying cause of the 
condition.  However, our understanding of FXS has now progressed to a stage where 
treatments selected to target the underlying cause are now being trialled. Participation 
in clinical trials of new medicines for the condition are essential to determine whether 
these treatments are actually effective. Experience conducting research studies at The 
Patrick Wild Centre into this condition has suggested that some families are reluctant 
to take part in clinical trials making recruitment challenging. Therefore, this study was 
designed to understand barriers to participation specifically amongst patients with 
the condition and their families. 
The primary aim of this study was to identify the barriers to research participation in 
order to maximise recruitment for future studies. The second aim of the study was to 
find out how barriers to clinical trial participation could be overcome.  Questionnaires 
and focus group interviews were used to address these aims.  A quantitative 
questionnaire was completed by 328 parents, carers, family members of individuals 
with FXS or by individuals with FXS. Following this, three focus groups took place in 
Chelmsford, Bristol and Edinburgh. Participants were identified from the UK fragile 
X society mailing list by a member of the Fragile X Society, The Patrick Wild Centre 
mailing list and the questionnaire was advertised on the Patrick Wild Centre website, 
Facebook and Twitter feeds.  
This study clearly demonstrated that there are many different reasons for not taking 
part in clinical trials of medications.  However, the main barriers to participation were 
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concerns about possible side effects, travel, requirement for blood tests and perceived 
or real financial reasons. When these barriers were explored further during focus 
groups it was evident that these barriers were not as clear as they may have appeared 
and had many complexities to them. The main way to overcome barriers that was 
repeatedly discussed in each focus group was the importance of accessible 
information in helping families to understand the study including any potential safety 
issues. This study highlights that there is no one thing that researchers can do that will 
work for everyone, and that they must look at ways to make their research more 





















Fragile X Syndrome (FXS) was first discovered in 1943 by James Martin and Julia Bell 
who found a form of mental disability which was linked to the X chromosome (Martin 
and Bell, 1943). A chromosomal test was then developed in 1969 by Herbert Lubs who 
observed a constriction on the end of the long arm of the X chromosome giving a 
‘fragile’ appearance  (figure 1) , thus giving rise to the name ‘Fragile X Syndrome’ 
(Lubs, 1969). It was not until the late 1970’s that testing for the condition became 
widely used when Grant Sutherland found a way to detect the ‘fragile’ site which led 
to the first diagnostic test for the condition (Sutherland and Hecht, 1985). At this time 
little was understood about the inheritance of this disorder as it was not typical of 
other X linked conditions, in that there were reports of unaffected males transmitting 
a mutation to their daughters. In 1985 Stephanie Sherman studied the inheritance 
pattern more closely which lead to the suggestion that the syndrome was a two-step 
process; the first step being a ‘premutation’ where there are no clinical symptoms 
present but which conferred increased risk of a symptomatic child, and the second 
mutation being a ‘full mutation’ for which symptoms are characteristic of FXS.  
In 1991 a team of scientists sequenced the gene at the constricted part of the X 
chromosome and identified an expanded triplet (CGG) repeat sequence in the 
promotor region, which caused fragile X syndrome.  They named the gene  FMR1. The 
expansion of the CGG repeat sequence in the promotor region silences the gene, 
preventing its transcription and subsequent translation into the Fragile X Mental 
Retardation Protein (FMRP) resulting in the characteristic features of FXS (Verkerk et 
al., 1991).  
FMRP, which is an RNA binding protein, is widely expressed, predominantly within 
brain neurons. Here it binds to RNA through its three binding domains. FMRP binds 
to target mRNAs to repress translation during transport to postsynaptic dendric 
spines (Levenga et al., 2010). FMRP is essential for proper synaptic plasticity, neuronal 
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morphology and cognitive development, therefore its absence leads to varying levels 
of intellectual disability. Due to the location of the FMR1 gene and the presence of a 
second unaffected X chromosome females are typically less affected than males 
(Crawford et al., 2001). 
Figure 1: Fragile X Chromosome (Figure adapted from encyclopedia britania) 
 
 
FXS is thought to be the most common inherited form of intellectual and 
developmental disability and the most common known single gene cause of autism 
(Hagerman et al., 2010).   However, the heterogeneity of FXS has historically made 
diagnosis challenging and the variation of symptom severity especially when 
comparing males and females adds to the difficulty in assessing prevalence. Prior to 
1991 clinical diagnosis was made by carrying out mental and physical examinations 
alongside cytogenetic testing, a method which Sofocleous et al. (2009) have argued is 
much less reliable than the most up to date approach which uses a polymerase chain 
reaction (PCR) based technique and Southern blotting. A systematic review published 
in 2014 (Hunter et al., 2014) has reported that the prevalence of individuals with a full 
mutation is 1.4 per 10,000 males and 0.9 per 10,000 females. The number of people 
with a premutation was 11.7 per 10,000 in males and 34.4 per 10,000 in females. These 
numbers are lower than a previous systematic review which was carried out 10 years 
previously (Song et al., 2003), which highlights the difficulty to date in acquiring an 




Individuals who are premutation carriers usually have normal IQ. Males may be more 
likely to display attentional problems, executive dysfunction, social deficits and 
obsessive compulsive behaviours (Farzin et al., 2006). Some male premutation carriers 
over the age of 50 develop neurologic deficits previously thought to have been 
parkinsonism; it is now recognised as fragile X-associated tremor/ataxia syndrome 
(FXTAS) (Jacquemont et al., 2004). Female permutation carriers are more likely to 





The phenotypes associated with the full mutation syndrome vary considerably among 
patients. These can include; prominent forehead, narrow face, protruding ears, high 
arched palate, strabismus, macro-orchidism, low IQ, and connective tissue dysplasia 
including hyperflexibility of the joints (Hagerman and Hagerman, 2002, 2014, Kidd et 
al., 2014). The physical characteristics of FXS are often fairly subtle so often testing is 
carried out after failure to meet developmental milestones such as mild motor and/or 
language delays (Maes et al., 2000). Autistic like behaviours are also considered when 
looking for a diagnosis; commonly these include features such as hand biting, hand 
flapping and poor eye contact (Garber et al., 2008). Concurrent medical conditions 
associated with the condition are usually relatively mild, they include; 
gastroesophageal reflux disease, seizures and mitral valve regurgitation (Hagerman 
and Hagerman, 2002).  
 
Autopsy studies have suggested that while the brains of people with FXS appear 
grossly unaffected, dendritic spines are longer and immature in appearance (Irwin et 
al., 2001). Elongated dendritic spines, a major site of synaptic transmission on cortical 
neurons, have been associated with intellectual disability, including in Down 
syndrome and Rett syndrome (Kaufmann and Moser, 2000).  For this reason it is likely 
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that many aspects of FXS can be accredited to altered synaptic development and 
plasticity.  
 
Learning difficulties and behavioural features 
 
Learning difficulties in people with FXS can vary from mild to severe however it is 
most common to be within the mild to moderate range of intellectual disability, with 
males often more affected than females. Around 60% of females with a full mutation 
will have some form of learning disability. Difficulties with learning include; 
problems with creative thinking, poor hand eye coordination, sequential processing, 
creative problem solving, visual motor planning and problems with short term 
memory (Hodapp et al., 1990).  Often there are problems with receptive language so 
understanding can be much greater than that which might be indicated from the level 
of expressive language (Turk, 2011). There are inevitably problems with speech.  
Speech is often delayed and distorted and commonly displays echolalia, 
perseveration, cluttering and dysarthia (Sabaratnam, 2006). 
 
Attentional problems and restlessness can be present in anyone with FXS with any 
degree of learning disability and can severely impair their ability to learn or engage 
with a task. Behavioural features include: restlessness, impulsivity, over activity, 
difficulty waiting, difficulty focusing on tasks, easily distracted and difficulty with 
transitions (Tsiouris and Brown, 2004). Common behavioural symptoms displayed by 
those affected by FXS are also often similar to those affected by Autism Spectrum 
Disorder (ASD), with around 30-50% meeting criteria for an ASD diagnosis.  This 
would suggest, as argued by (Devitt et al., 2015), that autistic symptoms may be under 
genetic control. It has been shown that there are noticeable developmental patterns of 
adaptive behavioural function which shows a relative downward trajectory in those 
with FXS compared to their peers during childhood resulting in them falling further 
behind (Klaiman et al., 2014). 
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Anxiety is one of the most prevalent characteristics of FXS (Cordeiro et al., 2011). It 
decreases the ability for the individual to think clearly, adapt to situations and carry 
out everyday tasks causing shyness and upset by novel people or environments (Reiss 
and Freund, 1992). There are two main types of anxiety in FXS; anticipatory anxiety 
and social anxiety. If a person with FXS has previous experience of a situation they 
may be fearful in the future if it was unpleasant, thus causing anxiety due to learned 
experience. Individuals with FXS tend to display symptoms of social anxiety rather 
than social indifference.  In social settings common features displayed are; gaze 
avoidance, self-injury, repetitive behaviours such as hand flapping, mood swings, 
challenging behaviour, emotional difficulties, difficulty initiating and maintaining 
friendships and insistence on routine. Scientists have tried to measure social anxiety 
in FXS by looking at mice to find out whether this is caused by the loss of FMR1 
(Spencer et al., 2005, Spencer et al., 2008). Their conclusions demonstrated that mice 
had normal levels of social interest and social recognition; however they showed high 
levels of social anxiety, suggesting that the loss of FMR1 gene function results in 
altered anxiety and social behaviour (Spencer et al., 2005, Spencer et al., 2008). 
 
Many people with FXS have sensory processing and integration problems (Hagerman 
and Hagerman, 2002, Riley, 2011). The most troubling feature of FXS reported is 
sensory based hyperarousal (Reiss and Hall, 2007). Often individuals may struggle to 
manage information if more than one sense is activated at the same time, causing them 
to feel overwhelmed and become upset or anxious. This in turn can lead to difficult or 
repetitive behaviours due to poor adaptability and coping. The feeling of being 
overwhelmed occurs as a result of deficits in sensory–motor gating which causes 
difficulty filtering auditory stimuli (Yuhas et al., 2011). There are two main categories 
for sensory problems; sensory discrimination and sensory modulation both of which 
individuals with FXS are likely to experience resulting in difficulties in learning and 
skill development (Baranek et al., 2002). Individuals with FXS tend to become 
hyperaroused by normal or excessive sensory information. Hyperarousal is associated 
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with an increase in the autonomic nervous system and heightened sympathetic 
arousal meaning that in individuals with FXS there is a lower threshold for 
responding to sensory and emotional stimuli.  
 
Theories for treatment 
The current medical treatments for FXS are primarily symptomatic in nature; and 
include the use of selective serotonin reuptake inhibitors for anxiety, stimulants for 
attention deficit hyperactivity disorder and antipsychotics for irritability or aggressive 
behaviour.  However, our understanding of FXS has now increased to a stage where 
treatments selected to target the underlying neurobiology are now being trialled. 
Whilst these appear to be successful in mice they have however failed to benefit 
patients with FXS. Efficacy has been demonstrated in one controlled trial of 
minocycline (Hagerman and Polussa, 2015) and potentially also arbaclofen (Berry-
Kravis et al., 2012). There have also been some open label trials which have shown 
acamprosate and lovastatin to be of some varying benefit to individuals with FXS 




Minocycline is a commonly used antibiotic traditionally used for the treatment of 
acne. Minocycline is also an inhibitor of an enzyme called matrix metalloproteinase 9 
(MMP-9).  MMP-9 has been found to be overactive in FXS and is thought to be 
involved in synaptic plasticity (Szklarczyk et al., 2002) thus impacting on memory and 
learning (Bilousova et al., 2009).  To the author’s knowledge there has only been one 
randomised controlled trial of minocycline in fragile X syndrome (Leigh et al., 2013).  
This trial was a crossover design with participants allocated to 3 months treatment 
with either minocycline or placebo and a beneficial effect of minocycline was seen on 
one of the primary outcome measures; no effects on secondary outcome measures 
18 
 
were observed (Leigh et al 2013). This is consistent with the idea that minocycline has 
an effect in FXS by inhibiting the enzyme MMP-9. The same group later reported that 
the improvements observed were correlated with reductions in MMP-9 activity 




Arbacolfen (the (R)-isomer of racemic baclofen, a readily available anti-spasmodic 
medicine) showed initial promise.  Arbaclofen is a GABA-B agonist, hypothesised to 
be of benefit to people with FXS both directly, by increasing GABAergic inhibition, 
and indirectly, through downstream effects on glutamate signalling (D’Hulst and 
Kooy, 2007). There has only been one published trial of arbaclofen in people with FXS 
to the author’s knowledge. This was a crossover design, randomised placebo, 
controlled study where participants received the maximum dose of arbaclofen for a 
period of 4 weeks (Berry-Kravis et al., 2012) The study failed to show a significant 
effect of arbaclofen on the primary outcome measure, however it did report a number 
of beneficial effects on secondary and post hoc measures. Following on from this a 
larger Phase III trial of arbaclofen was conducted in FXS with an 8 week treatment 
period.  Again however no significant benefit of the medication was shown on the 
primary outcomes and its development has been subsequently halted. Detailed results 




Lovastatin is licenced as a drug that is widely used to help lower cholesterol. It is a 
HMG-CoA reductase inhibitor. It is believed that Lovastatin can correct cognitive 
deficits by reducing activation of the Ras-ERK intracellular pathway through 
interfering with the Ras and cell membrane interaction process and in doing so, 
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prevent the pathological changes in FXS that cause excessive protein synthesis. One 
study which looked at enhanced activity of the Ras pathway in FXS in an FMR1 
knockout mouse (Osterweil et al., 2013) found  that lovastatin was able to correct the 
excessive Ras activity and block the mGluR5 mediated epileptiform activity.  
Lovastatin was found as a result of this to reduce hyper excitability in the visual cortex 
of the knockout mouse. An open label trial of Lovastatin in children with FXS where 
15 people were treated with escalating doses for three months (Caku et al., 2014) has 
shown positive results. This trial showed the drug was well tolerated with minimal 
side effects and significant improvement was demonstrated in both the primary and 
secondary outcome measures in twelve out of the fifteen people who took part.  A 
larger randomised controlled trial would be required in order to obtain efficacy of the 




Acamprosate is predominantly used to help maintain abstinence from alcohol in 
adults with alcohol dependency. It has the ability to bind to NMDA glutamate 
receptors (Hagerman and Polussa, 2015). Two studies have been carried out (Erickson 
et al., 2010, Erickson et al., 2013) trialling Acamprosate in FXS. The first – an open label 
study in three adults demonstrated improvements in both clinical global impression 
scale (CGI-I) measurements and in language. The second – a ten week open label trial 
in twelve children demonstrated improvements in CGI-I, social behaviour, 
inattention/hyperactivity and reductions in social impairment. Blood tests showing 
levels of plasma brain derived neurotropic factor also showed an increase after 
treatment with Acamprosate, however this was not in correlation with treatment 
response measures. A phase II multi centre double blind placebo controlled trial has 






A novel connection between metabolic glutamate receptor (mGluR) signalling and the 
fragile X phenotype was discovered in 2002 when it was shown that mGluR activity 
is significantly increased in the hippocampus of animals lacking FMRP (Huber et al., 
2002).  
 
The mGluR theory explains the immature synaptic connections seen in both animal 
models and humans and is the leading theory regarding the pathophysiology of FXS 
(Bear et al., 2004) (figure 2).  The mGluR5 theory is that the lack of FMRP leads to 
excess mGluR mediated protein translation in the synapse.  In turn this leads to 
changes in synaptic plasticity, in particular increased hippocampal long term 
depression.  This then predicts that reducing mGluR5 activity will reverse the excess 
protein translation and restore the synaptic phenotype. It was this theory which led to 
the development of mGluR5 antagonists as a treatment for FXS. When tested in animal 
models significant rescue of many phenotypes was shown, however when used in 
human trials efficacy criteria have not yet been met (Pop et al., 2014, Hagerman et al., 















Having discussed what FXS is and the current theories for treatment options, it is 
apparent that not enough is known about how the condition can be treated in order 
to provide a better quality of life for people. Whilst some treatments have appeared 
successful in mice models there has been a disparity when the theory is translated to 
humans and many treatments options still require further testing e.g. lovastatin and 
minocycline. There are also other medications that are being considered that require 
testing e.g. alcobra and cannabinoids. It is important, research, specifically clinical 
trials, are carried out in order to find out more. If sufficient numbers of participants 
cannot be sought for these trials then clinicians are less likely to fund or use 
interventions (Oliver et al., 2002). Specifically, if numbers of participants of 
underrepresented minorities (such as people with intellectual disabilities) are not 
obtained for clinical trials there is a danger that existing health disparities will be 
increased. The NHS plan (Department of Health 2000) committed to including more 
people with learning disabilities in participating in research, so it is important to make 















A clinical trial is any study which assigns participants or groups of participants to a 
specific health related intervention to measure and evaluate the effects on health 
outcomes according to a research protocol. Interventions can be drugs, devises or 
procedures. Often a comparison is made between a new approach and an existing 
already available one, or to a placebo. Clinical trials are conducted in order to ensure 
safety and efficacy of new treatments or interventions. They are performed so that 
medical knowledge can be added upon and treatment, diagnosis and prevention of 
diseases and conditions can be better understood. Adequate inclusion of participants 
in clinical trials is essential in order to ensure development and improvement in all 
areas of healthcare (Chalela et al., 2014). Without adequate representation in clinical 
trials it is impossible to assess differential effects or to ensure generalizability to trial 
outcomes (Ford et al., 2005). It is therefore important that efforts are made to include 
people by identifying barriers, despite these often being complex, and doing all that 
can be done to address these.  
 
General trial barriers 
While there are few papers that examine the barriers specifically related to FXS it can 
be helpful to look at barriers to research participation in general. A systematic review 
by (Ross et al., 1999) found that there were five main categories for barriers to 
recruitment in randomised controlled trials for patient participation.  These were: 
 Additional demands 
 Additional appointments and procedures 
 Causing discomfort or inconvenience 
 A strong preference for or against a particular treatment e.g. not wanting to 
take experimental medication or take placebos  
 Patients found uncertainty to be difficult 
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Additionally information and informed consent were concerns as people wanted 
more information. The review concluded that to overcome barriers, study demands 
should be kept to a minimum and patients should be supported throughout their 
decision whether or not to take part in a clinical trial. 
 
More recently barriers and promoting factors to participate in early stage clinical trials 
were examined in one study (Chalela et al., 2014) which found the main barriers to be 
socio economic, distrust of the medical system, fear/uncertainty and fantastic/spiritual 
beliefs. Factors promoting participation were potential symptom improvement, 
disease control, high quality medical care, hopefulness and social influences.  
 
A further recent review to identify strategies to address barriers to clinical trial 
participation (Heller et al., 2014) found combined strategies to be the most useful. 
These included; spending time before protocol design developing recruitment 
strategies, engaging with medical professionals, gaining community trust, onsite 
meetings within busy community practices to increase provider engagement, 
community education about clinical trials, transport assistance and offering more 
flexible hours. 
 
Intellectual disability trial barriers 
 
It is well known that the health of people with intellectual disability is often poor and 
numbers for participation in research studies in this population can be difficult to 
achieve (Gilbert, 2004, Lennox et al., 2005). A review highlighting the difficulties in 
conducting a randomised controlled trial of health service interventions in intellectual 
disability highlighted three main concerns; ethical, methodological and service 
capacity (Oliver et al., 2002), which echoes the results from the systematic review by 
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(Ross et al., 1999), that barriers to participation not only arise from a lack of people 
participating but rather there are additional barriers with regards to clinician 
participation. Both clinicians and services require time and additional support to 
recruit people for clinical trials.  Concerns about altering the clinician/patient 
relationship act as barriers towards the facilitation of research and require addressing. 
This research is further reiterated in a report (Lennox et al., 2005) which breaks down 
barriers in recruitment to intellectual disability research into two main categories, 
sectoral and research process. Sectoral barriers refer to a lack of accessibility to people 
and funding constraints, while research process barriers refer to study specific 
difficulties and ethical considerations. Ethical concerns were also perceived to be a 
major barrier to recruitment to a medication trial (Oliver-Africano et al., 2010), 
alongside other barriers including refusal to give consent, refused tablets, side effects, 
and primary carer antagonistic towards clinical trials. 
 
Prior to the 1960’s there is no evidence of inclusive research in learning disabilities. 
Rather, those with learning disabilities were tested or observed but their views were 
never asked (Walmsley, 2001). Historically research with people with learning 
disabilities has been more research on, rather than research with, carried out by detached 
researchers, deciding on research questions and developing what they feel to be 
suitable measures (Kiernan, 1999). “Advances in the social position of people with learning 
disabilities have led to a situation where research and evaluation studies are increasingly 
required to include the views and opinions of people with learning disabilities” (Gilbert, 2004). 
Both funders and ethical committees have begun to stress the importance of patient 
and public involvement. Gilbert (2004) highlights that there are challenges in doing 
this for example time, commitment, financial resources, flexibility and patience; 
however (Gilbert, 2004) outlines benefits for people with learning disabilities such as 
facilitating people to have accesses to published literature and allowing them to help 
shape research questions. Involving people with learning disabilities could help to 
assist participation in research from an early stage therefore improving recruitment. 
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Fragile X syndrome trial barriers 
 
Carrying out clinical trials in FXS holds several challenges. Due to the heterogeneous 
population there is potential for each subpopulation to have differential therapeutic 
responses, this alongside the lack of specific outcome measures means that it can be 
difficult to measure changes. Early clinical trials have highlighted three specific 
challenges; heterogeneity, lack of biomarkers and no specific sensitive outcome 
measures. (Jacquemont et al., 2014). Future clinical trials in FXS need to be designed 
in a way that tracks changes over a longer period of time looking at multiple symptom 
domains and perhaps stratifying patients according to FMR1 (Jacquemont et al., 2014) 
 
A key paper when looking at patient and family barriers to clinical trial participation, 
specifically in FXS, came from the MIND institute in California (Chechi et al., 2014). 
This paper assessed motivational factors and barriers for participation of 
underrepresented minority children in clinical trials for FXS and other 
neurodevelopmental disorders. Whilst this study looked in detail at FXS it focused 
specifically on children, although no age range is specified. They carried out a survey 
which was administered only to parents whose children were already attending the 
MIND institute for either treatment or to take part in research. The survey had twenty 
nine multiple choice questions which had additional space to provide further 
information. A total of one hundred responses were collected and analysed. A large 
focus was made on the reasons why people chose to or chose not to take part in clinical 
trials, for example low income families or age of child at time of diagnosis. They found 
the top two motivating factors for taking part in a clinical trial were to help find a cure 
and to help relieve symptoms related to a child’s diagnosis. They reported a significant 
association between willingness to take part and; higher household income, and those 
whose children had been diagnosed earlier in life. The most common reason for 
choosing not to take part was requiring more information about side effects and 
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concerns over being given a placebo. No link was found between choosing to take part 
in clinical trials and gender, age, race and level of education. 
 
It is therefore clear from the evidence that all clinical trials hold their own unique 
challenges and participants often are sceptical of experimental medicines. For 
example, concerns include the lack of assurance that they would not be given placebo, 
the potential for side effects, reluctance to devote the time needed to the clinical trial 
for additional appointments and procedures, and not being given enough 
information. These were also true when barriers specifically for FXS trials examined. 
Given the only study focusing specifically on barriers to clinical trial participation in 
FXS was done purely based on a survey of those already attending a single FXS clinic, 
there is a knowledge gap requiring more in-depth and generalisable information 
about barriers to participation and how these can be overcome. This may help make 
recommendations for future research study design, and thus improving the 


















As reviewed in the previous chapter, recruitment to research studies for people with 
intellectual disabilities is a recognised struggle. Some work has been done to identify 
some of these challenges alongside strategies to overcome them (Lennox et al., 2005, 
Heller et al., 2014, Chechi et al., 2014, Ross et al., 1999, Oliver et al., 2002, Oliver-
Africano et al., 2010). Only one of these studies related specifically to FXS and was 
conducted in a sample of individuals attending a single FXS clinic within a research 
centre in the USA.   
Experience conducting research studies in FXS in our own research centre in the UK 
(the Patrick Wild Centre) has also suggested that recruitment to take part in clinical 
trials when testing new medications can be extremely challenging. Despite 
widespread circulation of information, there are a very limited number of families 
who contact the centre when they hear about clinical trials and many of those who do 
get in contact have concerns and reservations about participating.  
It is important to fully establish what the patient and family associated barriers to 
participation are so that they can be addressed enabling successful recruitment to 
future clinical trials. It is notable that similar research conducted in prostate cancer 
trials showed that by integrating qualitative methods prior to randomised control 
trials, recruitment can be improved (Donovan et al., 2002). This study demonstrated 
that a simple identification of the core preventative barriers allowed trials to be 
tailored with these borne in mind and communication and recruitment strategies 
could be developed to address these head on.   
 
Aims 
The primary aim of the study was to find out what prevents people with FXS from 
taking part in clinical trials.  
30 
 
The secondary aim of this study is to find out how barriers to clinical trial participation 
could be overcome amongst patients with fragile X syndrome and their families in 




A mixed method design was used, collecting both quantitative and qualitative data. 
A quantitative questionnaire was completed by parents, carers, family members of 
individuals with FXS or by people with FXS themselves. Following this, three focus 
groups took place in Chelmsford, Bristol and Edinburgh. All of the participants who 
took part in the focus group had taken part in the quantitative questionnaire. 
 
Using both quantitative and qualitative methods for data collection meant that while 
it can be difficult to ensure complete objectivity during focus groups due to the 




Quantitative research gathers numerical data to provide objective measurements 
which can be generalised across groups or people to explain a phenomenon. It was 
considered to be useful in this study to collect quantitative data as it allows responses 
from a larger number of people than could be sought from any other method.  Using 
quantitative methods increases the application of findings to the wider population 
and allows a more accurate representation of the population. Using this method meant 
there was a greater degree of objectivity by avoiding variables and personal bias 
ensuring validity and reliability of results. Finally collecting quantitative data allowed 





Qualitative research aims to understand and make sense of individual’s experiences 
by investigating meaning and significance thus allowing for a greater insight to the 
finer nuances of an individual’s report and looking in greater detail at the person’s 
understanding (Silverman, 2005). Use of a qualitative methodology allows a 
naturalistic and interpretive approach to systematically investigate human 
experiences, linking the patient’s life and behaviour with their thoughts and feelings 
(Flick, 2009). It presumes that no objective conclusion can be ascertained, rather 
accepting that individuals will form their own subjective take from interactions, 
experiences and cultural norms (Denzin, 1984) and rejects the postmodernist concept 
of accepting knowledge as purely objective truth (Kvale, 1995). Qualitative research 
therefore facilitates a deeper insight into several different levels of knowledge which 
is unachievable using quantitative methods alone. The aim of this research was to find 
out what put people off taking part in previous clinical trials and to discover if there 
was anything that could be done for future clinical trials to make them more accessible 
for those who wish to take part. It was for this reason that a phenomenological 
research method was used as this method provides a rigorous, critical and systematic 
investigation of phenomena in order to capture individuals’ experiences. 
 
Phenomenology 
Phenomenology is used to describe phenomena, or appearance of things as lived 
experience (Cohen, 1987). It is a rigorous, critical and systematic method of 
investigation with lived experience as its central focus (Speziale et al., 2011). “The 
purpose of phenomenological enquiry is to explicate the structure or essence of the lived 
experience of a phenomenon in the search for the unity of meaning which is the identification 
of the essence of phenomenon, and its accurate description through the everyday lived 
experience” (Rose, 1990). As this study aims to understand people’s reasons for not 
taking part in research and take into account their experiences of past research and 
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lived experience of having a child with FXS to see how barriers can be overcome, this 
was deemed to be the most appropriate research method. Purposeful sampling was 





General inclusion and exclusion criteria 
In order to participate in the study all individuals had to be over the age of 18. They 
had to be a family member or a carer of someone with a diagnosis of FXS. People with 
a diagnosis of FXS were included so long as they were able to read and write so they 
could complete the questionnaire. Both males and females were recruited. Individuals 
who could not read or write were excluded as they were required to complete the 
questionnaire without assistance from the research team. Only individuals who had 
completed the questionnaire were eligible to take part in a focus group. Written 
consent was collected from individuals who agreed to take part in the focus groups. 
 
Ethical considerations 
Prior to this research being conducted it was presented to an external ethics committee 
for review. They granted favourable ethical opinion based on the submission of an 
application form along with a protocol and supporting documentation. This was 
granted on the 2nd of April 2015. 
 
Implied consent was used for those taking part in the questionnaire (i.e. by completing 
and returning the questionnaire they were judged to have given consent).  However 
for those wishing to take part in the focus groups fully informed consent was collected. 
All participants were informed that they could withdraw consent at any time without 
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being required to give an explanation. No payment was given for those who took part 
however all travel expenses were reimbursed to ensure that no participant was left 
out of pocket. 
 
No benefits for taking part were anticipated, however participants were informed that 
information collected may lead to greater recruitment into clinical trials and that it 
could be possible the fragile x community could potentially benefit if new treatments 
are developed. 
 
Identification/ approach  
The bulk of participants were identified by a member of the Fragile X Society from the 
UK Fragile X Society mailing list, which contains over 1000 families. The Fragile X 
Society was formed in 1990 by families whose children had been diagnosed with 
Fragile X Syndrome. They provide support and information to families affected by 
FXS from those who share and understand their concerns and needs. They educate 
and inform the public and professionals about FXS in order to raise awareness and 
understanding of the syndrome and so improve the care of all people affected by FXS 
and encourage research into all aspects of FXS and publicise the results. 
 
The Society was involved in the early stages of the research project and in the 
development of the questionnaire to ensure they would be happy to support the 
study. They were provided with pre-made packs containing the questionnaire and a 
leaflet about the Patrick Wild Centre which meant the Society only had to add an 
individual’s address to each envelope before they were sent out.  
 
Furthermore, an email was sent using The Patrick Wild Centre mailing list to let 
people know about the study. All people on this mailing list were based in the UK and 
had given permission to be contacted with information regarding planned research 
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studies. This email was not targeted towards specific individuals but rather was sent 
to the mailing list as a whole.  
 
The questionnaire was also advertised on the Patrick Wild Centre website, Facebook 
and Twitter feeds. When the study was posted on the Patrick Wild Centre Twitter 
page it was retweeted by seven different organisations and therefore returned 
responses from all over the world.  
 
Participants were also identified by contacting people who have taken part in the 
fragile X registry project run by The Patrick Wild Centre who gave explicit permission 
to be contacted directly about future research.  
 
At the end of the questionnaire participants were asked to provide their contact details 
if they wished to take part in a focus group. However, those who provided their 
contact details did not automatically get to take part in a focus group. Focus groups 
were run in locations with a sufficient number of interested individuals, to ensure 
there were enough people to take part. A minimum of 10 people were invited to attend 
each focus group.  
 
Questionnaire 
The Questionnaire consisted of nine questions (see appendix 1). The questionnaire had 
the option to allow the participant to remain anonymous if they wished, however if 
they wanted to take part in the following focus group they had the option to leave 
their contact details. It was structured to ensure it took as little time as possible to 
complete to help encourage participation, by including as many tick box options as 
possible. There were boxes provided to give the option to provide further details if 




Participants were asked about any previous clinical trial participation and their 
thoughts on taking part in future trials including any barriers that they perceived. This 
allowed for exploration of reasons why families may not consider taking part in 
clinical trials and what they thought could be done to help encourage participation. 
They were also asked what kind of experience they had to help contextualise the 
answers given in later questions. The Question ‘Please tell us things that you feel 
would make it difficult for you or your family member to take part in research. Tick 
all of those that apply and please state any additional issues under "other" if they are 
not listed’ was included to find out things that people might struggle with or find 
difficult that may lead to them choosing not to participate in a clinical trial.    
 
It was available on both electronic and paper form to help maximise recruitment. The 
electronic version was set up on Survey Monkey and the settings prevented it from 
being filled out by the same person multiple times. A total of 1001 questionnaires were 
posted out to people who had consented to be informed about research projects 
through the Fragile X Society. The electronic version was emailed to members of the 
Patrick Wild Centre friends list and was also advertised on both the Fragile X Society 
and The Patrick Wild Centre twitter and Facebook pages. 
 
Focus groups 
Focus groups were deemed to be the most appropriate method of data collection for 
the qualitative aspects of this project, as it was important to explore people’s views 
and experiences in considerable detail and within a cocreative environment.  It was 
thought that the group interaction in response to specific questions would provide 
valuable insights. The use of focus groups has become a popular approach in 
qualitative health research. A focus group refers to a group discussion in which the 
researcher actively encourages group interaction and ensures that participants talk 
amongst themselves rather than relying solely on the researcher (Barbour, 2008). 
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Focus groups “tap into human tendencies. Attitudes and perceptions relation to concepts, 
products, services or programs are developed in part by interaction with other people. We are 
a product of our environment and are influenced by people around us”(Krueger Richard and 
Anne, 1994) p10-11. While it has often been argued that phenomenology and focus 
groups are incompatible (Webb and Kevern, 2001), for this study a particular 
phenomenon is being looked at and the group process of a focus group provides a 
good platform for participants to shared lived experiences and how these may or may 
not impact on taking part in clinical trials. Focus groups can be particularly useful for 
addressing the ‘why not?’ questions and to obtain perspectives on topics which 
participants may have spent little time thinking about (Barbour, 2008). 
 
Only people who completed the questionnaire were eligible to take part in focus 
groups. Three focus groups took place in locations picked based on where the 
maximum number to participants could be recruited in order to ensure as many 
people could participate. These were Chelmsford, Bristol and Edinburgh. 
 
Prior to conducting focus groups informed consent was sought from all participants.  
Each participant was given a detailed information sheet (see appendix 2) which 
contained contact details for the person carrying out the study but also an 
independent contact who was not involved or would benefit from the study in any 
way so that independent non biased advice could be given if required. The 
information sheet was issued to inform participants about the purpose of the research 
including possible benefits and risks of taking part. This was both for the participants’ 
and researchers’ protection, and is important to protect the participant from receiving 
potential emotional, psychological and social harm that they may experience if they 
were not correctly informed (Gerrish and Lacey, 2010). At this time they were also 
given a copy of the consent form to read over to make sure they would be happy to 
take part. Subjects were informed that they had the right to withdraw at any time 
without giving a reason. After receiving the information sheet and consent form each 
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participant was then contacted by the researcher at least a week later to find out if they 
still wished to take part.  
 
The author was trained in conducting focus groups by attending a course run by the 
Social Research Association (SRA) to ensure they had the necessary skills to conduct 
these to ensure quality and integrity of data collected. Although the material that was 
discussed was not particularly sensitive, there was a small chance that the focus 
groups would identify issues that the participant may have required support with. In 
this case, the facilitator was trained to handle the matter delicately and provide the 
individual with the opportunity to discuss the issue further out with the focus group. 
If any issues were identified that required further support then the investigators 
would signpost the person appropriately, provided the individual had provided 
consent (e.g. through the fragile X society support workers, or the person’s GP). 
 
Focus group topic guide 
To ensure the continuity of the focus groups and that all necessary topics would be 
covered, a topic guide was developed (see appendix 3) that drew on the data collected 
from the questionnaires. The topic guide was designed to allow for a flexible interview 
style using open ended questions and suggested clarification questions and probes to 
ensure that everything was covered whilst encouraging the groups to take an active 
role in forming the knowledge generated. 
 
Rigour 
Reliability and validity are key concepts within qualitative research in order to 
establish veracity of findings. The criteria used to achieve these are credibility and 





Any study needs to be credible to ensure that the information being presented is 
believable and fits within the context of current literature and what is already known. 
In this study credibility was ensured by recruiting an appropriate sample. Other 
measures to ensure rigour include the following: 
 During each focus group the facilitator used clarification throughout to ensure 
that the facilitator’s understanding of what was said was correct. 
 All groups were audio recorded and transcribed by an external agency (TP 
Transcriptions Ltd) to ensure that actual words spoken were easily accessible 
for analysis. 
 After each focus group the contents of each group were discussed with a 
supervisor to reflect on findings and interpretation. 
 
Transferability 
As focus groups were carried out by those willing and able to attend they may not 
constitute a truly representative sample. In order to improve transferability and 
generalisability the following measures were taken: 
 The combination of quantitative data from the questionnaire alongside the 
focus groups provided evidence from a larger sample size. 
 The participants who took part came from a range of backgrounds and 
geographical areas within the UK ensuring that the thoughts and experiences 
of a broad range of respondents were included. 
 People were invited to take part in the focus groups who had said they would 
not consider taking part in research trials as well as those who said they would, 





Reflexivity is an important part of qualitative research as the preconceptions and 
subjectivity of the researcher can bias or contaminate the data captured. It is therefore 
important to avoid losing richness of data which comes from the intersubjective 
interaction (Seale, 1999). By engaging in reflective practice it is therefore possible to 
recognise the effects of subjective processes within research and determine whether 
this has had an effect on the understanding and representation of the interviewer’s 
subjective experience. While reflective practice has often been seen as self-indulgent 
and the emphasis often made on self-reflexivity (Riach, 2009, Finlay, 2002), being 
mindful of the processes and how preconceived epistemologies can influence research 
along with continual critique and awareness of the interviewer’s position in the 
process of collecting the data. Each interview was recorded using a voice recorder 
however as this method is unable to capture facial expressions, interactions between 
focus group participants and general thoughts from the interviewer were recorded in 
a field note journal immediately after each session. This kept track of assumptions as 
well as emotional reactions (Gilbert, 2001) this was not only for the group but also for 
the observer, to enable understanding through self-reflection and avoid self-
absorption (Lofland and Lofland, 2006, Kleinman and Copp, 1993). These notes were 
unable to be recorded during the focus groups as there was only one interviewer and 
taking notes may have disrupted the flow of conversation and there was a risk of the 
interviewer missing key parts of the discussion. A field note journal was used to aid 
analysis of the data and to reflect back on the interactions of the group including any 
potential influence by the interviewer over the discussion. 
 
Data management 
On their return each questionnaire was allocated an identifying number for storage 
purposes. In most cases the questionnaire was anonymous, unless the participant 
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provided their contact details for the focus groups. In this case the identifiable 
information was detached from the questionnaire.  
 
People who took part in the focus groups were allocated a unique code number to 
ensure confidentiality (Polit and Beck, 2004). A key to this code was kept in a locked 
filing cabinet separate from the data and consent forms. A further key was kept in a 
password protected file on a server that was only accessible through a password 
protected computer and which is distinct from the server where the data was held. 
This unique code number was used on all written data and any electronically held 
databases. Only the research team had access to this key to pseudonymise the data in 
order to prevent any breach of confidentiality. Any private data identifying 
participants was unable to be reported. The study adhered to the principles of Good 





The analysis for the data obtained from the questionnaires was conducted using the 
IBM statistical package for social science (SPSS) (IBM SPSS Statistics for Windows, 
Version 22.0. Armonk, NY: IBM Corp). SPSS was used to run Pearson’s Chi-squared 
tests to determine whether there were differences in the barriers identified between 
the two countries with the largest response rate and whether or not an interest in 
taking part in clinical trials made a difference to the barriers reported. 
 
Qualitative analysis 
Thematic analysis was used. Thematic analysis organises and describes data in detail 
and interprets various aspects (Braun and Clarke, 2006). This form of analysis was 
chosen due to its flexibility, allowing themes to emerge from the data rather than using 
a pre-existing theoretical framework. The recordings of the focus group were 
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transcribed by an external agency. While is often thought to be important for the 
researcher to immerse themselves in the data and that the transcription process can be 
a good way to do this (Bird, 2005),  it was felt that as the researcher carrying out 
analysis had facilitated the focus groups they had already begun familiarising 
themselves with the data so using an external agency would provide a more accurate 
transcription. The recordings were listened to by the researcher whilst reading the 
transcriptions several times prior to coding to help identify possible patterns and 
meanings, and to ensure data was accurately punctuated to ensure accuracy and that 
the meaning of data had not been altered (Gubrium and Holstein, 2002, Lapadat and 
Lindsay, 1999). This was used in conjunction with the field note journal kept for each 
focus group in order to assist recollections of the subtleties of the communication. 
Initial codes were then generated from the data. These codes were data driven and 
first performed manually and then Nvivo software (NVivo qualitative data analysis 
Software; QSR International Pty Ltd. Version 10, 2012) was used to assist with the 
systematic analysis and to ensure accuracy. Once the data was coded potential themes 
were developed, this was done by both the researcher who facilitated the groups but 
also an external researcher to ensure reliability and validity. The themes were then 
reviewed together and refined after considering the validity of each theme in relation 



















A total of 328 people completed the questionnaire. 148 people returned a paper 
version of the questionnaire and 180 completed it electronically. Figure 3 below shows 
the distribution of the number of results based on country completed. 90% of those 
who took part provided this information. 
 
Figure 3: Map demonstrating geographical distribution of responses 
 
Of the 328 people who took part, 94.5 were parents of a person with FXS, 3.37% were 





Figure 4: Link to FXS 
 
 
19% of people who completed the questionnaire had previously taken part in a trial 
of new medicines and 81% had not (figure 5). Of the people who had taken part in a 
previous trial 36.92% had a positive experience, 1.94% had a negative experience and 
20.39% reported having a mixed experience. 41.7% of people did not complete this 
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Figure 5: previously taken part in a trial 
 
 
Figure 6: experience 
 
 
45.69% would consider taking part in future clinical trials, 42.49% would maybe 












Have you or a member of your family taken part in 
trialling a new medication for Fragile X Syndrome?
Yes
No
If you answered yes, how would you 




Figure 7: Would take part in future trial 
 
Figure 8 summarises the barriers to participation which were highlighted through the 
questionnaire. These barriers can be grouped into three categories: Drug effects, study 
procedures and effects of study on wider life. Over a fifth of participants reported 
swallowing tablets, financial aspects, blood tests and travel as barriers to participation 
and nearly 70% reported side effects as a barrier. Of those who ticked ‘other’ over 50% 
of these responses fall under current categories. 10% were concerned about seeing 
benefits from a trial then having to stop the medication and 5% would struggle to take 
part due to their child not living with them. 10 % of the comments were general trial 
comments unrelated to barriers and the remaining 20% covered things like disruption 
















Would you or your family member consider taking 
part in a future clinical research trial of a new 
medicine for Fragile X Syndrome?
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Figure 8: Barriers to participation 
 
 
A large number of participants who completed the questionnaire were from the USA 
and this allowed a comparison between the UK and the USA to see if the different 
healthcare systems made a difference to the reported barriers. Table 1 reports these 
results. There were significant differences between the UK and USA on four barriers: 










Please tell us things that you feel would make it 
difficult for you or your family member to take part 
in research. Tick all of those that apply and please 




approved for use in FXS, meeting an unknown research team and visiting a new place 
were barriers compared to those from the USA (all p < 0.05), whereas a greater number 
of people from the USA felt that travel was a barrier to participation (p = 0.05). Over 
all there seems to be more barriers reported from people in the UK. 
 
Table 1: USA v’s UK barriers (significant results highlighted in bold) 
 
 
UK USA Chi2 p 
New medicine 24.4% 25.4% .037a .847 
Existing medicine 22.7% 9.3% 8.853a .003 
Blood tests 38.6% 29.7% 2.500a .114 
Travel 42.6% 54.2% 3.829a .050 
Unknown research 
team 
26.1% 14.4% 5.772a .016 
New place 29.0% 16.1% 6.455a .011 
Swallowing 
medication 
37.5% 28.0% 2.875a .090 
Time 30.1% 28.0% .157a .692 
Financial 30.7% 39.8% 2.622a .105 
Side effects 65.9% 61.0% .733a .392 
 
Table 2 shows a list of barriers broken down to show the percentage of people who 
would consider, would maybe consider and who would not consider taking part in a 
clinical trial, to highlight whether certain barriers are more likely to put people off 
taking part in clinical trials completely. There was a significant difference between 
those who reported that they would or would not consider taking part in a clinical 
trial on six barriers (all p <0.05).  
Those who said they would not participate more commonly reported that; taking a 
new medicine, taking an existing medicine not tested in FXS, blood tests, visiting a 
new place and side effects were barriers to participation, whereas those who said they 
would participate more frequently reported travel as a barrier. 
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Table 2: barriers and willingness to participate (significant results highlighted in bold) 
 Yes No Maybe Chi2 P 
New medicine 13.3% 48.6% 33.1% 25.42 <0.001 
Existing 
medicine 
7.0% 40.5% 22.6% 26.81 <0.001 
Blood tests 26.6% 40.5% 39.8% 6.26 0.04 
Travel 43.4% 32.4% 54.9% 7.24 0.03 
Unknown 
research team 
17.5% 27.0% 24.8% 2.87 0.24 
New place 16.1% 27.0% 29.3% 7.20 0.03 
Swallowing 
medication 
30.1% 29.7% 39.1% 2.83 0.24 
Time 23.8% 35.1% 33.1% 3.64 0.16 
Financial 31.5% 21.6% 39.8% 4.97 0.08 
Side effects 55.9% 81.1% 69.2% 10.29 0.006 
 
Focus groups 
A total of 182 people who completed the questionnaire provided contact details to be 
informed about taking part in a focus group. Of these 52 were contacted to take part. 
Focus groups took part in three locations throughout the UK to ensure as many people 
could take part as possible. The locations chosen were; Chelmsford, Bristol and 
Edinburgh. People who expressed interest in taking part who were not invited to take 
part were excluded based on living more than 70 miles from a focus group location. 
This was due to funding limitations. Of the people who took part 11 were parents, 1 
was a carer and none of the participants had FXS. Focus groups were asked about their 
current understanding of clinical trials, what they would want to know before 
deciding whether or not for their dependant to take part in a clinical trial and also 
asked to imagine they were designing a clinical trial and what they would take into 





Table 3: Focus group attendance 
Location Number contacted Number attended 
Chelmsford 22 3 
Bristol 19 6 
Edinburgh 11 3 
 
Data from the transcribed interviews was examined and was first split into 115 codes, 
which were then split into 6 categories and then grouped into themes with several sub 
themes. Much of the data overlapped between codes, categories and themes, however 
the process of assigning codes to different categories and then themes allowed 
exploration of the relationships amongst the issues arising from the data. 
 
The three major themes that emerged from the data were: trial challenges/barriers, 
strategies to assist participation, and motivating factors. The main themes and sub 
themes identified following the coding are shown in a thematic map in figure 9, and 












Figure 9: Thematic map 
 
 
Theme 1 Trial challenges/ barriers 
In each focus group the participants were asked about specific barriers to taking part 
in FXS clinical trials and those mentioned were very much in line with what was 
reported in the questionnaire. Several sub themes were included in the theme trial 
barriers/ challenges and these are described in more detail below. 
 
Travel 
There were varying degrees of how much of a barrier travel would be. The reason for 
travel being an issue was around the time it would take and the interruption to the 
patient’s routine. This was particularly reported to be an issue if several research 
appointments were required: 
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“It would have to be local” 
“I don’t have time to travel.. My boy loves travelling but we just can’t afford the time” 
Focus groups mentioned very little difficulties with regards to their child’s ability to 
travel on public transport or in a car, however it was alluded that this may not always 
be the easiest with one mother using sarcasm to show how difficult this can be: 
“Travelling with Fragile X is not, oh it’s a joy (laughter)” 
 It was mentioned in several of the focus group that given the option to travel together 
in a group would help to relieve some of the anxieties regarding this: 
“It would be friendly …it would be an anxious situation but if you knew you were going to 
fly together and meet at the airport..” 
 It was also mentioned that if the travel could be arranged for them so they did not 
have to organise it themselves, this would help to overcome travel as a barrier. For 
example, many people reported finding package holidays helpful, which arrange 
several aspects of travel for them when going on holiday: 
“I don’t mind flying up but once I get to Edinburgh I think oh what do I do now? Because 
normally when I go on holiday you get all the pick-ups and they know where you are going 
and the hotel you are going to so it’s all taken care of so you don’t have to worry about it” 
 
Procedure related difficulties 
There were many concerns raised in the groups around their children’s ability to have 
their blood taken, being able to take medication and to cope with getting a scan. Many 
parents talked about previous experiences trying to give their child medications in 
different forms and discussed the need for researchers to have different options 
available: 
“My daughter will not and cannot take any medication in the form of tablets or medicine” 
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Taking blood came up as a barrier in all three focus groups and was repeatedly 
brought up at different occasions throughout each group: 
“I nearly had my fingers broken while [child] has been having their blood taken” 
This is however not something parents would opt out of if the option was there as the 
safety of the trial outweighs the difficulty of the procedure, unless assurances were 
not given about why the blood test was in the protocol in the first place and if it was 
not vital for the trial: 
“They are important so I am not sure they could be reduced in a trial” 
“I think they need to tell you why they do the blood tests then you would know” 
 
Side effects/safety 
As demonstrated from the quantitative element of the research, the safety of the 
patient is a significant potential barrier to participation in any clinical trial.  In fact for 
a majority, this is the single most important factor in consideration.  The focus groups 
brought this issue to light in even greater detail. From the very beginning of the 
session there was widespread agreement that the potential side effects and toxicity of 
new medication is of primary concern.  As one participant stated when asked what 
their primary concerns were:  
“Safety is number one” 
Another participant took this further to comment on the drugs themselves when used 
in clinical trials: 
“I am very very wary of the toxicity” 
As previously mentioned this highlights the need to ensure that these concerns are 
addressed from the outset of any clinical trial.   
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One participant commented on the issues they had had in previous trials that have 
had a knock on impact on future participation. The participant focused on a challenge 
which is specific to Fragile X Syndrome in terms of their child’s inability to verbally 
express the issues she was experiencing, which for this participant was attributable 
directly to the trial drug itself:  
“[child] Non verbal…so when you’re talking about drug trials... [child]  would cry and you 
wouldn’t know why” 
The overall concerns of new clinical trials in terms of side effects were effectively 
summarised by one participant who stated that:  




The environment relates to where the trial should take place. Each focus group was 
asked about trial locations for example clinics that were further away and would 
require travel, local clinics or trial visits taking place at home. Based on the 
questionnaires it was thought that as travel was one of the most common barriers and 
people would prefer to have visits completed at home, however this was not the case 
for everyone. A few participants felt it would be better to go somewhere else out with 
their home in case there were any negative consequences associated with the trial that 
they did not want to be associated with home: 
“I don’t want home being associated with blood tests” 
There were some participants however that would favour trial being done in their 
own home as it would mean they did not have to travel and would take up less time. 
They also felt their child may be more relaxed: 
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“I think it would have to be local familiar territory” 
“Based at home would be nice” 
With regard to environment this overlapped with the issue of time, with many 
reporting they would need trials to take place more locally to fit in with their child’s 
routine. The severity of the environment being a barrier related to how often the trial 
visits would take place: 
 “They have to be local. It has to be out with school time” 
 
Consent 
As the majority of people attending the focus groups were parents to a child with 
Fragile X Syndrome one of the main concerns was over them consenting on behalf of 
their child. They felt if they could be of help they would take part in any trial that 
could potentially help their child however consenting on behalf of them to take part 
was a much bigger concern: 
“Saying yes for someone else is a big responsibility” 
“Do whatever you want to me but my child is different” 
Whilst the parents understood that legally they were able to consent on behalf of their 
child they felt there was a big difference consenting on their behalf to take part in a 
drug study over other studies that do not involve medicines. Participants still felt that 
even for other studies that didn’t involve new medicines consent can be tricky as their 
child with FXS wouldn’t be able to understand why they would be taking part. 
Therefore consent may always be a struggle in all trials: 
“I don’t think he would really understand why we were doing it so that’s not informed 
consent is it?” 
“I don’t think he would understand what I was trying to explain to him” 
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Theme 2 Strategies to assist participation 
The focus groups were asked about overcoming barriers and what they would like to 
know about before signing their dependant up to taking part in a clinical trial. They 
were also asked about what they would do if they were designing their own clinical 
trial to help with recruitment. The main subthemes which came out were; information 
giving, environment, preparation, support, flexibility and time. 
 
Information giving 
The focus groups made it very clear that they wanted as much information on the trial 
medication as possible and having this information would help alleviate anxieties 
about side effects and safety. They also reported wanting very easy to understand and 
read information which breaks things up into chunks. It was suggested to have a short 
and long version so if someone was interested they can get more detailed information. 
Families specifically want to know what the medicine is trying to do: 
“I’d be happy if I knew that the side effects weren’t going to be anything too major” 
The participants felt if they had lots of information about the trial medication and were 
made aware of previous safety trials and potential side effects then they could weigh 
these up and would be far more likely to participate: 
“..sign up for it straight away if something had already gone through safety trials” 
“I’d have more worries about a completely new drug than one that’s already been used and 
obviously the side effects were known” 
Many people reported wanting to meet the research team in person and have the 
opportunity to ask questions in an informal environment with the chance to listen to 
other people’s questions. It was stressed that the researchers should use language that 
is easy to understand. They also felt this was important to build a trusting relationship 
with researchers. They recognised that perhaps it would not be possible for all people 
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to attend these events therefore it was important to use as many forms of media as 
possible to inform people about trials and specifically from a trusted source for 
example the Fragile X Society: 
“A table or stand at Society events... a face to face thing” 
“Combination of all media” 
It was also reported that families did not necessarily feel they could contact the 
researcher to discuss the trial in more detail and that often they would see something 
in the information sheet and instantly dismiss the trial. Therefore having a line in the 
information sheet which explicitly says that researchers welcome families to contact 
them to talk about any concerns and how the trial could be made to work for them, 
would be beneficial: 
“I think families want to meet you and talk” 
 
Environment 
Whilst environment was discussed under barriers to participation it was also felt that 
this could assist participation in clinical trials. Whilst talking about environment one 
of the participant commented: 
“We don’t give our children enough credit for adapting to new things, they surprise you” 
They went on to say that this does not need to be a barrier and sometimes people with 
FXS surprise them by coping well with new places and situations, which opens doors 
to other new experiences that the family did not think were possible. 
It was also mentioned that if trials take place in local places with local clinicians then 
this could be a real positive for the family as they would have a contact who knew 
their child and that their child felt comfortable around: 
58 
 
“Local hospitals, local clinicians.. local clinicians getting to know them, actually that would 
be good for us” 
 
Preparation 
Before taking part in a clinical trial many of the participants mentioned the importance 
of preparing their child to help them understand what they were going to be doing 
and why. It was discussed that if the trial team could provide easy to understand 
information they could share with their child that would be very beneficial: 
 “A story board of what is going to happen” 
It was also highlighted that if their child got the preparation to get blood taken for the 
trial then this would be beneficial and make future routine tests at the doctors much 
easier: 
“Win win: you get the blood sample, we get a kid that is probably going to be able to give 
blood in the future” 
Participants also mentioned it would be beneficial for the trial team to provide packs 
specifically aimed at helping to overcome some of the things that their child may 
struggle with, for example education packs so parents can work through these with 
their child before attending clinic visits: 
“Education packs for kids so that they understand the process of taking blood” 
 
Support 
In each group there was a positive discussion towards travelling to research 
appointments with other families to gain social support and have contact with families 
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in a similar situation to themselves. They also reported that this could help to reduce 
some of the stress of travelling: 
“With other families, they understand so I can just relax a bit” 
It was mentioned that travelling with others would not only take away the stress, but 
would also be a good opportunity to get social support from other families who 
understand, which families don’t always feel that they have time for: 
“you could get a minibus , you could make friends locally” 
“it would be a real draw” 
“with other families they understand so I can just relax a bit” 
 
Flexibility 
Flexibility of the trial was mentioned frequently. Participants discussed in particular 
the barrier of their child’s ability to take medication, however if there was more 
flexibility and the trial drug could be given for example via a patch, liquid or 
suppository this would make a big difference to whether or not their child could take 
part: 
“If it’s drugs, personalise the method of administration” 
It was also suggested that being flexible with trial visit location would be helpful so 
doing some visits locally and only travelling for certain visits that were required to be 
done further afield: 
“You need a combination don’t you? You need something you do locally…then maybe a 
biannual trip further afield" 
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Also being flexible with regards to the testing required could make a difference to 
whether or not someone would take part in a trial for example, taking blood in a 
different way such as using a finger prick sample, or if possible take samples less often: 
“Find a different way to get bloods that would be good” 
 
Time 
It is important to take into account the distance to be travelled when designing the 
visit schedule as this can impact on the amount of time that is taken up by the trial. 
Families reported being happy enough to travel to a research appointment once every 
couple of weeks if the appointment was closer by but would only realistically manage 
a biannual trip if it was further away and required more time: 
“Within an hour’s travel might work” 
 
Theme 3 motivating factors 
There were many different motivating factors for parents/carers wanting their 
dependant to take part in clinical trials however the same reasons were echoed in 
every focus group. There was a feeling of not wanting their child to change but rather 
to see improvements in certain areas of their lives such as anxiety, learning and 
concentration: 
“the biggest thing for my son is anxiety” 
“anxiety and concentration” 
They wanted their child to be able to achieve more, not necessarily in school but rather 
to be able to go into social situations or crowded places without feeling uncomfortable 
to help them live a fuller life: 
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“Anything that helps my daughter to be able to say her own name…anything that helps her 
achieve a bit more in life” 
 
The importance that clinical trials take place to further understand FXS and to help 
the next generation was echoed in each focus group: 
“Trials have to be looked at as positive” 
“If we didn’t try things we wouldn’t get anywhere would we?” 










Chapter 5: Summary, discussion and future directions   
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This chapter brings together both the quantitative and qualitative data from the study. 
Hypotheses and research questions will be discussed in depth and strengths and 
limitations from the study will be highlighted, including using two different methods 
of data collection. Implications for future practice will also be identified. 
 
Discussion 
This study was conducted to identify barriers to clinical trial participation with 
families affected by fragile x syndrome and how these can be overcome. The study 
used both quantitative and qualitative methods to gather data. A mixed methods 
approach has not been used in previous research carried out in this area. Using a 
mixed methods approach was a way to add more depth to the data to explain why 
certain barriers exist and how families feel barriers can be overcome, or whether it is 
even possible to overcome barriers to research. Thus moving away from looking at 
barriers within the clinical setting that prevent participation and looking at the views 
from people who wish to take part but don’t feel they are able to. The existing research 
suggests barriers to research participation in FXS include lack of information, side 
effects and concerns about being given a placebo and that people wanted to take part 
in trials in this field to help find a cure and to help relieve symptoms (Chechi et al., 
2014). This study aimed to build on this research to find out if there were other barriers 
that had not been found previously, and perhaps identify country specific barriers as 
previous research has only been carried out in the United States of America. It also 
aimed to see if it was possible to overcome trial barriers and if so what the families 
think researchers could do to help increase participation. 
 
Barriers 
The primary aim of the study was to find out what prevents people with FXS from 
taking part in clinical trials. The study demonstrated clearly that there are many 
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different reasons for not taking part, however the main barriers to participation raised 
from the questionnaires were concerns about possible side effects, travel, requirement 
for blood tests and perceived or real financial reasons. When these barriers were 
explored further during focus groups it was evident that these barriers were not as 
clear as they may have initially appeared and had many complexities to them. The 
barriers from the study taking into account both quantitative and qualitative data can 
be split into three categories:  
 
1. Drug effects: Taking a new medicine, taking an existing medication which has 
not be licenced in FXS and side effects. 
2. Study procedures: blood tests, unknown research team, visiting a new place 
and swallowing medication. 
3. Effects of study on wider life: Travel, time and financial 
 
1. Drug effects 
Side effects were reported to be a barrier by 68% of the total sample, and 81% of those 
who said they would not currently consider taking part in a clinical trial because they 
were worried about side effects. Side effects were also reported in the literature to be 
one of the main barriers to participation in clinical trials more generally (Oliver-
Africano et al., 2010, Ross et al., 1999, Chechi et al., 2014). With such a large proportion 
of people reporting that this particular barrier would prevent them from participating 
in research it was important to explore this further in the focus groups. The focus 
groups reported that there was great concern over side effects due to their child having 
difficulty reporting any side effects back to their family as a result of being non-verbal 
or having language difficulties. There was also concern that side effects may display 
themselves in other ways, such as behaviourally, and this could be distressing to 
families as they may not be able to tell if there was a problem or what the specific issue 
was. This was particularly a concern with some of the treatments that had severe side 
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effects such as hallucinations. The safety of the medications is paramount to families 
demonstrating the need for as much safety information to be available as possible. 
 
Taking a new medicine was reported by 27% and taking an existing medicine which 
has not been licenced for use in FXS was reported by 18% of people who participated. 
While these were not some of the highest reported barriers they are highly significant 
when looking at whether people would or would not consider taking part in new 
clinical trials (table 2). If these were reported as the barriers to participation then they 
are less likely to take part in a future clinical trial with just under half of people who 
wouldn’t take part in a future clinical trial reporting it as a barrier.  As with side effects, 
this suggests that it is important to have as much information as possible on the 
medication so that people can make an informed choice. 
 
2. Study procedures 
It appeared from the questionnaires that blood tests were a common trial barrier and 
on initial analysis that having blood tests in a trial would prevent people from taking 
part. It was surprising to find that when blood tests were discussed in the focus groups 
this was perhaps not such a deal breaker to participation as was initially thought. 
Taking blood was discussed as a challenge and something that people with FXS may 
struggle with, however it was not something that would solely put families off 
participating. Notably when discussed whether to have a choice to opt out of blood 
draws at study visits to increase participation this was met with caution from families 
who felt if an ethics committee had approved the protocol with blood tests in it then 
there would need to be assurances as to why it would be ok from some people not to 
have blood tests and still participate.  
 
 Taking part in a clinical trial with unknown research team and visiting a new place 
were highlighted by around a fifth of those who completed the questionnaire. These 
were not significant barriers in impacting on whether or not someone would or would 
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not take part in a clinical trial. Under 1/3 of people who wouldn’t take part in a future 
trial reported these as being barriers. In focus groups families discussed that it would 
be preferred to meet the research team beforehand to build up a relationship and trust 
to help ease anxiety. It was also discussed if the research could be done by local 
clinicians this could provide a benefit to families as they would be able to make contact 
with people local to them and build up a relationship so in the future if there were any 
issues they would have a point of contact that their child felt comfortable visiting in a 
place that was familiar to them. 
 
Swallowing medication was reported as a barrier by 35% of participants. The same 
percentage of people reported this as a barrier regardless of whether or not they would 
choose to take part in a future clinical trial. In focus groups different methods of 
medication administration were discussed as some people with FXS regardless of their 
age would not swallow any medication. Having flexibility as to administration 
method would allow more people to take part who wouldn’t be able to if there was 
only a tablet form of medication. Suggestions given by families were an enema (as 
their child wouldn’t be able to spit it out) or liquid form.  
 
 
3. Effects of study on wider life 
The second highest reported barrier to participation was travel (49%). From the focus 
group discussions it became clear that travel was not simply about the mode of 
transport and associated anxiety but also included the time it takes, how often and 
possible interruption to routine.  People reported that it was reasonable to travel short 
distances on a regular basis however would be willing to travel further if it was a 
couple of times a year. Families reported being anxious about travelling alone and 
how their child would feel about going on a plane or a train if they had never done 
this before but were open to the idea of trying it particularly if they could do this with 
other families who could provide peer support. It is interesting to note that while 
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travel was reported as one of the main barriers to participation, 44% of people who 
reported this to be a potential barrier would still consider taking part in a clinical trial. 
 
As no research participant should ever be out of pocket for participating in research 
in the UK and with all travel expenses and meals being paid for by the study budget, 
looking at financial reasons as a barrier to participation was interesting to explore 
further. The results from the focus groups showed that this was a barrier due to being 
unaware that all research costs would be covered. The opinions of those who attended 
the focus groups showed that this was not as much of a barrier as it originally 
appeared and that the financial concerns they had regarding participation was more 
about having to take time off work. Very little time was spent discussing this barrier 
perhaps reflecting the results from the questionnaire which showed that this was more 
of a concern of people who completed it from the USA. 
 
Time was reported by roughly a third of participants. People were concerned how 
much time travelling to research appointments would take and how many 
appointments they would need to attend. This was felt to be a barrier as they didn’t 
want to interrupt their child’s routine too much as they felt this could be disruptive. 
Interestingly they were not concerned about the length of time the research 
appointment itself would take. 
 
Overcoming barriers 
The second aim of the study was to find out how barriers to clinical trial participation 
could be overcome. The study data acquired from the focus groups demonstrated 
clearly that there are many different ways that research teams can help to overcome 





The main way to overcome barriers that came up repeatedly in each focus group was 
the importance of accessible information in helping families to understand the study 
including any potential safety issues in a variety of easy to understand formats. They 
felt a good way to get information on the study would be to meet the research team at 
information evenings and be given an opportunity to ask questions in an informal 
setting. Not only would this help alleviate anxiety about the study itself but would 
also be a good opportunity to meet the research team and build up a relationship with 
them helping to increase trust. The families suggested that if questions could be asked 
at an early stage that this could help to reduce anxieties and that families would be 
more likely to find a way to overcome perceived barriers in order to take part in a 
study. 
 
 Participants suggested travelling together in groups to provide peer support and to 
make it more of an event.  Participants expressed that ideally research visits would 
take place nearby and at the most every couple of weeks. It was felt that many could 
realistically only manage a biannual appointment if the visits took place further from 
home. Therefore by adapting the study design to allow for this would help to improve 
participation by more families 
 
Interestingly when the issue of blood tests was raised in focus groups families felt that 
they would not want to compromise safety for convenience and that they would 
rather withdraw from a study than continue without blood tests if these were felt to 
be necessary. Whilst interesting, this is somewhat of a moot point as regulators would 
not allow participants to continue in trials without adherence to the required safety 
blood testing schedule. Instead it was suggested by the families that a better way to 
overcome concern about phlebotomy would be to provide education packs in advance 





The study also found that a barrier to clinical trial participation was the result of a 
perceived lack of knowledge of trials taking place and as a result not enough known 
about them. Participants discussed their wish for wider advertisement of the trials 
through support groups, e.g The Fragile X Society, and online forums, as this was not 
something they would commonly seek out and search for themselves. 
 
USA vs UK  
Looking at the data comparing the USA and the UK responses provides some insight 
into why some people reported certain barriers and whether there are UK or USA-
specific barriers to participation. The data shows that people in the UK predominantly 
perceive there to be more barriers to taking part than those in the USA. The significant 
differences in perceived barriers are with regards to: taking an existing medicine, 
travel, meeting an unknown research team and visiting a new place (all p <0.05). These 
seem to be much more prominent concerns for respondents from the UK. Reasons for 
this may stem from the different health care systems; with higher baseline levels of 
psychotropic medication use and more frequent health care professional 
appointments in the USA as a result of more specialist clinics. A higher percentage of 
people in the USA reported travel and financial concerns as being potential barriers 
than those in the UK. We suspect that this is largely accounted for by the geographical 
differences of the country, with there being shorter distances required to travel for 
participants in the UK.  Given that most studies include travel expenses for 
participants, it is not clear why those in the USA reported greater concern about 
financial burden; we speculate whether it may be related to the greater distance 
required to travel and thus the necessity for participants and their families to take 
leave from their paid employment in order to attend trial-related appointments. Both 
people in the UK and the USA reported concern about side effects to be the largest 
barrier to clinical trial participation. The focus groups emphasised that accessible 
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information and the ability to discuss concerns with the research team at an early stage 
would be potential ways to overcome this barrier. 
 
This study highlights that while there are many things that can be done to help 
overcome barriers to participation there is not a fix that will work for all families. 
Researchers must look at ways to make their research more individual, flexible and 
accommodating. A positive outcome from the study is that 88% of people who 
completed the questionnaire said they either “would consider” or “would maybe 
consider” taking part in a clinical trial. This apparent appetite for participation 
highlights the need for researchers to make clinical trials more accessible to families 
by overcoming individual barriers that families may face. It is encouraging to note 
that of the 19% of people who had previously taken part in clinical trials only 2% 
reported having a negative experience. Advances in making research more accessible 
and enjoyable will hopefully mean that higher numbers will be able to take part in 
future clinical trials.  Hopefully this will result in a greater range of intervention and 




This study clearly shows the FXS clinical trials have a long way to go in reducing the 
barriers to participation to ensure whose who wish to take part are able to. It is 
imperative that future researchers use what has been learnt in the study when 
designing future clinical trials in order to recruit the numbers needed for a successful 
trial.  Potential trial modifications include: 
 
1. Providing more information in accessible and easy to understand formats 
including safety data. 
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2. Holding information evenings where families can meet the research team and 
ask questions. 
3. Provide the medication in different forms e.g enema or liquid as well as tablets. 
4. Include as few blood draws as possible. 
5. Consider the number of visits required for the study and the travel and time 
that would be required. 
6. Provide story boards to help prepare people with FXS 
 
 
Strengths and limitations 
The study benefits from having a large number of questionnaire responses collected 
worldwide and focus groups taking place in both Scotland and England ensuring a 
broad representation which helps to increase applicability while avoiding the 
possibility that findings are due to unusual local circumstances. 
 
In addition, the study recruited mainly through the Fragile X society rather than being 
clinically derived, making this sample much more likely to represent the general FXS 
population than a clinic based sample. 
 
A further strength of this study was using a mixed method approach. Using both 
quantitative and qualitative data provided a different perspective on the issues 
explored. The findings from both sets of data support each other, and taken together 
provide a more meaningful data set for how families feel future FXS clinical trials can 
be designed to support participation. 
 
Despite people from 13 countries across 5 continents completing the study, the results 
are still limited by a relatively small sample size.  It must be also acknowledged that 
the population taking part in the study are potentially biased towards those already 
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interested in research (as this was how the sample sent paper questionnaires were 
identified) and to those who are actively engaged with fragile x communities online.  
This potentially excludes those without internet access and who those who are not 
even thinking of participating in research.  Thus, these results must be seen in the 
context of barriers to research who are at least already contemplative of participation 
in research. 
 
A further limitation of this study was that small numbers attended two of the focus 
groups due to difficulties on the day or family commitments; although this shows the 
difficulties that families affected by fragile x syndrome face and further highlight the 
need for research to be made as easy as possible for them to participate in if families 
would like to do so. 
 
Finally, trial barriers were suggested in the questionnaire therefore potentially 
influencing the responses given. However, the focus groups were carried out over 6 
months after the questionnaire was completed which likely reduced the risk of 
participants from focusing on only the suggested barriers. 
 
Future directions 
The findings from this study suggest many areas for further research in this area. One 
main area would be to further investigate trial barriers worldwide in order to 
determine whether the trail barriers found in this study relate in other areas of the 
world or whether the UK faces individual barriers. 
 
Another interesting study to lead on from this work would be to examine the influence 
of participant characteristics on ability to take part in clinical trials.  For example, 
whether having a child with different severities of FXS or a comorbid diagnosis, such 
as autism, has an impact on ability to participate in research and whether different 
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strategies would be required to improve participation.  It may also be helpful with this 
to consider number of siblings and sibling diagnosis. 
 
Case studies showing perspectives of families attitudes and perceived barriers before 
taking part in a clinical trial and then after having taken part would make for an 
interesting comparison and could potentially be very useful when informing families 
about future clinical trials. 
 
Gaining information from people themselves with FXS to see how they feel about 
taking part in clinical trials and what they think researchers could do would provide 
an interesting and valuable insight to guide how future research could be carried out. 
 
It would be useful to gain insights from clinicians and service providers to see what 
their opinions are of clinical trials of medicines in FXS and what the barriers would be 
for them to build on the work of (Oliver et al., 2002). 
 
Conclusion 
It has been 73 years since FXS was first discovered and 50 years since testing for the 
condition has been widely used. In this time understanding of the biology and effects 
of the condition have improved and testing is more commonly carried out at an earlier 
stage in a child’s development. However this increased knowledge has not transferred 
into the development of medication to help treat FXS specifically with many clinical 
trials failing to show improvement in primary outcome measures. The current study 
revealed that there are many things that researchers can do to help include 
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Appendix 1: Questionnaire 
 
Kennedy Tower 





Enclosed is a short survey asking about your feelings on taking part in research for 
people affected by Fragile X. It would be great if you could fill out the survey (shouldn’t 
take longer than 5 minutes) and send it back it to us in the freepost envelope. 
The reason we are asking families to do this is to give us an idea about how people 
feel about taking part in research into new medicines for Fragile X. We want to make 
it easier for people with Fragile X and their families to work with researchers in the 
future. Experience conducting research studies in fragile X syndrome has suggested 
that some families are reluctant to take part in clinical trials of new medications. If 
numbers cannot be sought for these trials then clinicians are less likely to fund or use 
interventions. We aim to identify barriers to research participation in order to maximise 
recruitment to future studies. 
Our team at the Patrick Wild Centre aims to improve understanding of Fragile X 
syndrome in order to help improve outcomes for those affected.  We have enclosed a 
leaflet to tell you a bit more about what we do.   
To achieve this, we really need the involvement and support of people with Fragile X 
and their families. Please take part in this survey so we can find out more about your 
needs and opinions on research.  
We would be really grateful for your help with this survey.  
Kind Regards 
 
Sarah Wright      Dr Andrew Stanfield 






Identifying barriers to clinical trial participation with families 
affected by fragile X syndrome (IBX) 
 
County/ region of residence:   
 
Are you 
 A parent of someone with fragile X? 
 A carer of someone with fragile X? 
 Do you have fragile X syndrome? 
Have you or a member of your family taken part in trialling a new 
medication for Fragile X Syndrome? 
Yes/No 
If yes; How would you describe your experience?   
Positive/negative/mixed 




Would you or your family member consider taking part in a future clinical 
research trial of a new medicine for Fragile X? 
Yes / No/ maybe 





Please tell us things that you feel would make it difficult for you or your 
family member to take part in research. Tick all of those that apply and 
please state any additional issues under “other” if they are not listed 
 Taking a new medicine which is not currently available 
 Taking an existing medicine which has not been specifically 
approved for Fragile X syndrome 
 Blood test 
 Travel (air, train,bus etc) 
 Unknown research team 
 Visiting somewhere new 
 Swallowing tablets 
 Time 
 Financial 
 Concern over side effects 
 Other 
 





Please tell us things that you think would encourage people to take part 
in trials of new medicines  









Do you have any worries or fears about you or your family member 
taking part in trials of new medicines? 
Yes/No 





If there was a new treatment (medicine or otherwise) available for fragile 
X syndrome, what would you most like it to help with? (e.g. these could 

















We would like to thank you for your time taken to complete this Survey it 
is very much appreciated. 
Following on from this Survey we would like to ask families and carers to 
take part in small group discussions to explore key points further. If you 











Appendix 2: Information sheet 
                                                                                            
 
Participant Information Sheet 
Identifying barriers to clinical trial participation with families 
affected by fragile X syndrome 
You are being invited to take part in a focus group as part of a research study. Before 
you decide whether you would like to take part, it is important that you understand why 
the research is being done and what it will involve. Please take time to read the 
following information carefully. Talk to others about the study if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Please take 
time to decide whether or not you would like to take part. 
What is the purpose of the study? 
The reason we are asking families to do this is to give us an idea about what stops 
people taking part in research of new medicines. We want to make it easier for people 
with Fragile X and their families to work with researchers in the future.  
Why have I been invited to take part? 
You have been asked to take part as you indicated on the questionnaire that you filled 
out previously that you would like to be considered to take part.  
Do I have to take part? 
It is up to you to decide whether or not you wish to take part.  If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a consent 
form.  If you decide that you will take part you are still free to withdraw at any time and 
without giving a reason.  If you choose to withdraw from the study identifiable data 
already collected may be retained and used for the study. 
 
What will happen if I take part? 
 
You will be invited to attend one of the focus groups that we are running throughout 
the UK. The focus group will consist of around eight people should last roughly 45 
minutes. At the start of the focus group you will be asked to complete the consent form 
and will be given an opportunity to ask any questions you may have. The group 
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facilitator will bring up broad key themes from the questionnaires and invite you to 
discuss these in more detail. The focus group will be recorded and then transcribed to 
allow the discussions to be accurately analysed. The transcription will be completed 
by an experienced transcription service who confirm that information will be kept 
strictly confidential. 
 
What will I have to do? 
 
You will be invited to discuss themes that have been brought up from the 
questionnaires. It will be up to you how much you detail you wish to go into and how 
much you wish to disclose. 
 
What are the possible benefits of taking part? 
 
We do not anticipate that this study will benefit participants directly.  However, it may 
help us to design better future trials and are easier to take part in. Should it lead to 
greater recruitment into clinical trials, it is possible that the fragile X community will 
benefit if new treatments are developed. 
 
What are the possible disadvantages and risks of taking part? 
 
You will be required to give up your time to travel for the research and also the time 
taken to participate. 
 
Although the material to be discussed is not particularly sensitive, there is a small 
chance that the focus groups may identify issues that you may find upsetting. 
 
What happens to the information collected? 
 
The information we collect will be stored in paper form and on a secure computer at 
the University of Edinburgh.  We allocate a secret code number so that if anyone saw 
this information they would not recognise them.  The key to this code is kept separately 
from the data.    
All the information we collect during the course of the research will be kept strictly 
confidential and there are strict laws which safeguard your privacy at every stage.  
Sometimes we may want to share the data collected with other medical and scientific 
researchers.  In these cases, we do not share any identifiable information like their 
name and address, so the people we share the data with would not be able to 
recognise you from it.     
 
Will you be paid for taking part? 
 
We will not pay you for your time but we cover any travel expenses or food that you 
have bought when coming to see us. 
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What will happen to the results of the research study?   
We will write up the results from the study as a publication. This will be in a specialist 
medical journal. We will also write a report for the Fragile X Society newsletter and 
present the findings at various conferences.  However, your personal details will not 
appear in any report or publication arising from the research. 
Will my taking part in the study be kept confidential? 
All the information we collect will be kept strictly confidential and there are strict laws 
which safeguard your privacy at every stage. If you choose to take part in a focus 
group you will be allocated a unique code number which will not be shared with anyone 
outside the research team. 
Do the study investigators make any money from my participation? 
The study investigators are not paid anything for including you in the study, other than 
their ordinary salary. 
Who has reviewed the study? 
The study has been reviewed by the local Research Ethics Committee.   
 
If you have any further questions about the study you can discuss them with 
Sarah Eley who is running the study (0131 537 6673 or s.eley@ed.ac.uk) 
 
If you wish, you could contact Professor Stephen Lawrie (0131 537 6671) who is 
not involved with this study and could give impartial information about it.   
If you wish to make a complaint about the study please contact the University of 





Appendix 3: topic guide 
Barriers to clinical trial participation 
Topic guide 
 confidentiality 
 Take turns, listen, be respectful 
Introduction (10 mins) 
 Want to find out what you know 
 Want to work with you to better design clinical trials 
 tell me a bit about yourself – your name and why you were interested in coming 
along 
 tell me about your child with FXS 
 
If I say ‘clinical trial’ what does that make you think? (10mins) 
 Write down the first 3 things that come into your head 
 
From this point on when we talk about clinical trials we are talking about trials 
of new medicines 
If we were to ask you to take part in a clinical trial what sort of things would you want to 
know about?(15mins) 
 How would you hear about it? 
 Specific barriers 
- What could be done to make you more comfortable about that? 
- What are your views and thoughts on that? 
- What’s the most important? 
 Opportunities/potential benefits? 
- Most important 
 
Imagine you woke up tomorrow and you were in a team designing a clinical trial what 
sort of things would you be thinking about? (15mins) 
 How would you let people know? 
 What would you do to encourage people? 
 What would it help with? 
 
